MWA
VRTX icon

MN Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

MN Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.41M Buy
3,157
+7
+0.2% +$3.26K 0.69% 28
2025
Q4 		$1.43M Buy
3,150
+266
+9% +$115K 0.72% 26
2025
Q3 		$1.13M Buy
2,884
+476
+20% +$199K 0.6% 35
2025
Q2 		$1.07M Sell
2,408
-16
-0.7% -$7.37K 0.62% 38
2025
Q1 		$1.18M Sell
2,424
-539
-18% -$251K 0.69% 38
2024
Q4 		$1.19M Buy
2,963
+235
+9% +$109K 0.67% 34
2024
Q3 		$1.27M Buy
2,728
+65
+2% +$31.2K 0.72% 31
2024
Q2 		$1.25M Buy
2,663
+33
+1% +$14.3K 0.72% 31
2024
Q1 		$1.1M Hold
2,630
– – 0.68% 32
2023
Q4 		$1.07M Buy
+2,630
New +$972K 0.74% 32

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

MN Wealth Advisors's VRTX Position: Q1 2026 in Review

MN Wealth Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 0.22% in Q1 2026, buying an estimated $3.26K and bringing the position to 3,157 shares worth $1.41M. The position accounts for 0.69% of the portfolio, ranked #28.

MN Wealth Advisors first reported a position in VRTX in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.43M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • MN Wealth Advisors held 3,157 shares of Vertex Pharmaceuticals worth $1.41M as of Q1 2026.
  • MN Wealth Advisors bought 7 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.26K.
  • Vertex Pharmaceuticals made up 0.69% of MN Wealth Advisors's portfolio in Q1 2026, its #28 holding.
  • MN Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
  • MN Wealth Advisors's Vertex Pharmaceuticals position peaked at $1.43M in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on MN Wealth Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.